UROV News and Press, Urovant Sciences Ltd. From 11/19/20

Extension study demonstrates favorable results in long term treatment of overactive bladder with vibegron, including improvements in incontinence efficacy, quality of life endpoints and with good tolerability Long term EMPOWUR extension study data featured in an oral presentat...

RM LAW Announces Investigation of Urovant Sciences Ltd. PR Newswire BERWYN, Pa., Nov. 18, 2020 BERWYN, Pa. , Nov. 18, 2020 /PRNewswire/ -- RM LAW, P.C. announces an investigation on behalf of Urovant Sciences Ltd. ("Urovant" or the "Company") (NASDAQ: URO...

NEW YORK, NY / ACCESSWIRE / November 18, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: BioSpecifics Technologies Corp. (NASDAQ: BSTC ) ...

The acquisition of Urovant Sciences by majority owner Sumitomo significantly undervalues the company's lead asset vibegron. The buyout price implies approximately $250 million in peak sales for vibegron in the OAB market. Other shots on goal for vibegron and the company's second a...

Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning. on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks rebounded Friday as the rotation to economically sensitive industries regained momentum, despite rising COVID-19 cases that could lea...

Shares of Urovant Sciences (NASDAQ: UROV) were skyrocketing 93.8% higher as of 11:40 a.m. EST on Friday. The huge gain came after the company announced that it has entered into a definitive agreement to be acquired by Sumitovant Biopharma for $584 million. Sumitovant Biopharma w...

Gainers: Urovant Sciences (UROV) +94%, Zomedica (ZOM) +35%, Ovid Therapeutics (OVID) +16%, Fulgent Genetics (FLGT) +12%, Myovant Sciences (MYOV) +11%.Losers: Cassava Sciences (SAVA) -26%, Allied Healthcare Products (AHPI) -24%, Biocept (BIOC) ...

Gainers: [[UROV]] +91.4%. [[NAVB]] +30%. [[AWX]] +20.4%. [[FTCH]] +13.2%. [[LI]] +11.2%.Losers: [[GFF]] -10.4%. [[REV]] -7%. [[UUU]] -6%. [[AMWL]] -5.3%. [[LMNL]] -4.1%. For further details see: LI, AMWL, FTCH and REV among after-hours movers

Urovant Sciences Shareholders to Receive $16.25 per share in cash Urovant Special Independent Committee of the Board Unanimously Recommends that all Shareholders Vote in Favor of the Transaction Agreement Represents Confidence in Urovant’s Future Success Transaction...

Sumitovant Biopharma and Urovant Sciences Announce Sumitovant's Acquisition of Remaining Stake in Urovant - Sumitovant Biopharma to acquire all outstanding shares of Urovant it does not already own - Transaction increases Urovant's ability to provide patient therapies and ac...